Partnering and/or collaborate with ENYO Pharma to develop new therapies
Partnering and collaborating in the life science industry is essential for the development of innovative drug candidates. Since the beginning, ENYO Pharma has worked closely with several academic institutions, researchers, hospitals and private companies to build a strong portfolio in various therapeutic areas.
Indeed, ENYO Pharma has developed an innovative and disruptive drug discovery engine allowing to develop patentable molecules directed against new therapeutic intracellular targets.
Thus, ENYO Pharma is open to collaborate and partner to develop some of its molecules with different chemistry patterns coming from its unique approach. Please do not hesitate to contact us if you are interested.
Our current collaborations
ENYO Pharma entered into a research collaboration with Dr. Fabiola Terzi, Research Director at Inserm Unit U1151. Dr. Fabiola Terzi is leading the ‘Mecanisms and therapeutic strategies of chronic kidney disease’ team at the Hôpital Necker Enfants Malades in Paris.
The Hebrew University of Jerusalem
A collaboration has been initiated with Professor Rachel Nechushtai from Hebrew University of Jerusalem on NEET proteins modulators in various indications. (Learn more)
The company has initiated a collaboration with Paris-Diderot University, Inserm Unit U941 (Institut Universitaire d’Hématologie) to discover new drugs against adenoviruses. (Learn more)
Imperial College London
A new research collaboration has started with Professor Julian Walters at Imperial College London. The main goal of these investigations is to evaluate the potential for therapeutic use of the FXR agonist EYP001. (Learn more)
ENYO Pharma has signed a collaboration agreement with Novadiscovery, which consists in accelerating and de-risking the clinical development of EYP001, a bile acid receptor agonist (the farsenoid X nuclear receptor or FXR). (Learn more)
Charles River Laboratories International and ENYO Pharma have initiated a collaboration to identify the mode of action of ENYO Pharma’s lead preclinical chemical series, EYP002, using Charles River’s newly acquired, molecular target identification tool: Capture Compound Mass Spectrometry (CCMS) technology. (Learn more)
The company collaborates with the group of Professor Patrice André, one of ENYO Pharma’s co-founders (Inserm U1111, Lyon, France), to develop a deeper understanding of how FXR agonists inhibit the replication cycle of Hepatitis B (HBV). (Learn more)
ENYO Pharma SA
321 avenue Jean Jaurès
69007 LYON, FRANCE